Drugs / YY001
YY001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06228846 | Jul 2022 → Apr 2024 | — | Shanghai Yuyao Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05743634 | Mar 2022 → Feb 2023 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06783114 | Sep 2024 → Sep 2026 expected | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06499688 | Dec 2023 → Mar 2024 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783114 ↗ |
| Known as | Rcombinant botulinum neurotoxin type A for injection | “Rcombinant botulinum neurotoxin type A for injection (YY001)” NCT06499688 ↗ |
| Known as | Recombinant Botulinum Toxin Type A | “Recombinant Botulinum Toxin Type A for injection (YY001)” NCT06783114 ↗ |
| Modality | Protein / enzyme biologic | “Biological: YY001” NCT05743634 ↗ |
| Route | Intramuscular | “Single treatment,intramuscularly injected into five sites.” NCT05743634 ↗ |